Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1141-1160 of 1,782 trials

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Sepsis Treatment: Aminoglycoside Antibiotics and Isolation

We are studying the effects of combining aminoglycoside antibiotics with standard care and the role of protective isolation in critically ill neutropenic patients with sepsis. Our goal is to see how these strategies impact survival and other health outcomes.

Healthy Participants>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Lung Cancer Treatment: CT-P51 vs. Keytruda

We are comparing the effects and safety of CT-P51 and Keytruda in patients with untreated metastatic lung cancer. This study aims to find out if CT-P51 works as well as Keytruda when combined with chemotherapy.

Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Tacrolimus and Blood Sugar Control in Dialysis Patients

We are studying how tacrolimus affects blood sugar levels in patients on hemodialysis waiting for a kidney transplant. This research may help improve diabetes management in these patients.

Hemodialysis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyNephrology

Rotator Cuff Disease: Botulinum Toxin Treatment

We are studying whether botulinum toxin can help reduce pain and improve function in people with degenerative rotator cuff disease. Participants will be monitored for effectiveness and any side effects over three months.

Shoulder Tendonitis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Advanced Melanoma: Regorafenib Treatment Study

We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.

Advanced Melanoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Extra-Mammary Paget's Disease: PAGETEX Device Study

We are studying the PAGETEX device to see if it helps control Extra-Mammary Paget's Disease of the vulva. The trial will also look at pain levels, quality of life, and patient satisfaction during treatment.

Paget's Disease of the Vulva6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Intracerebral Hemorrhage: Anticoagulation Strategies

We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.

Cerebral Hemorrhage1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Vericiguat Study

We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.

Heart Failure with Reduced Ejection Fraction (HFrEF)3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine

Hemorrhoidal Disease: RAFAELO® Procedure with Pain Management

We are studying whether adding perianal infiltration during the RAFAELO® procedure helps reduce pain after treatment for hemorrhoids. This trial aims to improve comfort for patients undergoing this procedure.

Hemorrhoids>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Metycor Study for Autonomous Cortisol Secretion

We are testing a new treatment to see if it improves blood pressure, glucose levels, and overall health in patients with autonomous cortisol secretion. The study also looks at effects on weight, bone health, and quality of life.

Mild Autonomous Cortisol Secretion6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Diabetes and Bone Health: Alendronate Study

We are investigating how the medication Alendronate impacts bone and blood sugar markers in individuals with type 1 and type 2 diabetes. This study aims to compare the effects between the two types of diabetes and different assessment methods.

Diabetes and Bone Health IssuesMonitoring phase (IV)Standard MedicinesDiabetologyEndocrinologyRheumatology

Yellow Fever Vaccination: Comparing Injection Methods

We are studying how different ways of giving the yellow fever vaccine affect the immune response in participants. This trial aims to find out which method may provide better protection and safety.

Yellow Fever3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Advanced Melanoma: Enfortumab Vedotin with Pembrolizumab

We are studying a combination of two treatments for patients with advanced melanoma who have been previously treated. The goal is to see if this combination is effective and safe for improving patient outcomes.

Metastatic MelanomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

HER2+ Metastatic Colorectal Cancer: Tucatinib Combination Study

We are investigating whether a new treatment combining tucatinib, trastuzumab, and mFOLFOX6 can improve outcomes for patients with HER2+ metastatic colorectal cancer compared to standard care.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology